Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Ribrag

Showing results (51-60 of 94) with videos related to

Pageof 10
Sort By:
La Revue De Medecine Interne|December 12, 2012
[A retroperitoneal fibrosis in a 38-year-old Egyptian man]A Danu, L Chalumeau, V Ribrag, et al.
Presse Medicale (Paris, France : 1983)|July 7, 1990
[Salvage chemotherapy of non-seminomatous germ cell tumors. Phase II trial of a combination of etoposide, ifosfamide and high-dose cisplatin]V Ribrag, J P Droz, C Bouleuc, et al.
British Journal of Haematology|October 29, 1998
Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT)L Castagna, A El Weshi, J H Bourhis, et al.
Leukemia|May 1, 1995
Prognostic value of c-mpl expression in myelodysplastic syndromesD Bouscary, C Preudhomme, V Ribrag, et al.
Leukemia|September 1, 1996
Aggressive acute CD3+, CD56- T cell large granular lymphocyte leukemia with two stages of maturation arrestR Tordjman, E Macintyre, J F Emile, et al.
Carcinogenesis|July 1, 1993
Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinomaF Janot, L Massaad, V Ribrag, et al.
Progress in Clinical and Biological Research|January 1, 1989
Phase II trial with etoposide (VP16) plus ifosfamide plus high-dose cisplatin (VIhP regimen) in refractory germ cell tumorsJ P Droz, V Ribrag, M Ghosn, et al.
Leukemia|April 6, 2013
A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progressionC Marty, C Lacout, N Droin, et al.
Leukemia|February 20, 2003
Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blastsV Ribrag, F Suzan, C Ravoet, et al.
Bone Marrow Transplantation|April 21, 2001
Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapyJ M Vantelon, J N Munck, J H Bourhis, et al.
Pageof 10

Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
La Revue De Medecine Interne|December 12, 2012
[A retroperitoneal fibrosis in a 38-year-old Egyptian man]A Danu, L Chalumeau, V Ribrag, et al.
Presse Medicale (Paris, France : 1983)|July 7, 1990
[Salvage chemotherapy of non-seminomatous germ cell tumors. Phase II trial of a combination of etoposide, ifosfamide and high-dose cisplatin]V Ribrag, J P Droz, C Bouleuc, et al.
British Journal of Haematology|October 29, 1998
Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT)L Castagna, A El Weshi, J H Bourhis, et al.
Leukemia|May 1, 1995
Prognostic value of c-mpl expression in myelodysplastic syndromesD Bouscary, C Preudhomme, V Ribrag, et al.
Leukemia|September 1, 1996
Aggressive acute CD3+, CD56- T cell large granular lymphocyte leukemia with two stages of maturation arrestR Tordjman, E Macintyre, J F Emile, et al.
Carcinogenesis|July 1, 1993
Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinomaF Janot, L Massaad, V Ribrag, et al.
Progress in Clinical and Biological Research|January 1, 1989
Phase II trial with etoposide (VP16) plus ifosfamide plus high-dose cisplatin (VIhP regimen) in refractory germ cell tumorsJ P Droz, V Ribrag, M Ghosn, et al.
Leukemia|April 6, 2013
A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progressionC Marty, C Lacout, N Droin, et al.
Leukemia|February 20, 2003
Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blastsV Ribrag, F Suzan, C Ravoet, et al.
Bone Marrow Transplantation|April 21, 2001
Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapyJ M Vantelon, J N Munck, J H Bourhis, et al.
Pageof 10